Exploring Exicure, Part 3 – Community Buzz
As a rule, we follow the technological advancements of corporate giants in tech health to help inform those of us individuals choosing to define for ourselves who we are and what we want to be. That means knowing the world and those tracking us, good and bad.
Incredible advancements are made every day by health companies seeking to do good in the world, no doubt. However, we need to follow and examine them to enhance our own capabilities and positioning. We are not victims, we are active agents in our lives. In this new topic within the theme of Health, we are exploring a company primed to give us the safe/effective delivery of next-gen nucleic acid therapies right into our cells and tissues that we’ve been waiting for since the dawn of the 21st century.
Getting the buzz is exactly that… diving into the headlines and news beats on Exicure so we can get a read on the pulse of the company in the broader community.
Getting the Right Guidance
For Exicure development on their tech isn’t the only thing they are focused on. By continuing to build with quality people in their representative fields, Exicure is better positioning the company to navigate the high-flying world of biopharma. Two of its latest additions help to illustrate exactly this: Elizabeth (Betsy) Garofalo, M.D. and Mr. Andrew Sassine to its Board of Director.
Elizabeth (Betsy) Garofalo, M.D. represents “25 years of experience in global clinical development and regulatory affairs,” and a significant culmination as the “Head of the Neuroscience Therapy Area at Astellas, Ann Arbor Site Head of Worldwide Regulatory Affairs at Pfizer, and Ann Arbor Site Head of Neuroscience at Pfizer.” So it would be safe to say it seems like she knows what she is doing.
As for Mr. Andrew Sassine, no slouch himself currently serves as CFO (Chief Financial Officer) and Board Member of Arcturus Therapeutics and is a former Fidelity Fund Manager.
Quality additions, both. By the way, if you didn’t check it out above, the named links above aren’t just the news story, they are the links to their Linked In Profiles… worth checking out, as it gives a deeper look into how they represent themselves in the community.
Broader Buzz on Tech
“I am excited to join the Exicure team and its distinguished Board of Directors… I believe their technology has the ability to change the face of medicine by expanding and facilitating the delivery of DNA and RNA medicines to new and more challenging diseases.”
– Andrew Sassine, Chief Financial Officer
and member of the board of directors of Arcturus Therapeutics.
He also serves on the board of directors of ICAD, Inc.
For Exicure, it is certainly about that game-changing tech and the quality people needed to bring it to life. As we see in the quote above, Exicure is attracting a great assortment of talent to its business as the tech presented by the company has such great potential. That potential is what we see developing in the community at large.
The headlines over the last year really speak for themselves and support this thesis…
1.
2.
The results of the study can be found here.
3.
New collaborations and a set of new positive developments from the results of investigative uses of the therapeutics offered by Exicure certainly point to a bright future.
Analysts and More Say Buy, Buy, Buy…
Insider sentiment, according to you Yahoo! Finance (above) remains strong. More importantly, despite heavy increases in value to the insider holdings, they have not been selling over the last year, demonstrating the belief that they are just getting started.
As of March 5, 2021, Directorstalkinterviews.com reported that Exicure had now received the considerations of 5 analysts “with a consensus rating is ‘Buy’. The range between the high target price and low target price is between 18 and 6.” That same article said the price at that day/time was 2.27 and would have a potential upside of 340.5%! Pretty darn impressive.
For others in the investment and finance community, they see incredible value in comparison to other stocks in their price range. Investors Observer stipulated exactly this when they promoted a “strong overall score (for Exicure) of 90 meaning the stock holds a better value than 90% of stocks at its current price.” Better yet, the headlines on their site (see above) indicate the market is taking notice and going Buy, Buy, Buy.
Closing Up, for Now
From new folks joining the team to headlines promoting promising results, and market makers moving toward Exicure, the future definitely seems brighter than ever for this young BioTech! At least, that’s what the buzz seems to be indicating.
That’s it on the buzz, but make sure to come back next week as we wrap up our Health exploration of Exicure. We’ll be pulling the whole series back together and offering our unique BCB Cyber conclusion on this technologically enhanced company for the 21st century and beyond. So make sure to check out that and all kinds of other incredible cyber-fuel for your cyberized needs in our daily blog.
As always, make sure we are thinking for ourselves out there, doing our own homework, and cyberizing our lives with the best in disruptive tech. We aren’t doctors or professional investors, we’re just the average guy out there in the free flow of the masses looking for understanding and wanting to share. For those fueled by health-tech make sure to explore our BCB Cyber Health Section in more detail! See you next time on BCB Cyber.